Vera Therapeutics (VERA) shares were weak on Friday, which Cantor Fitzgerald tells investors is a clear buying opportunity in anticipation of the Phase 3 ORIGIN readout of atacicept in the second quarter of 2025. The firm, which has an Overweight rating and $100 price target on the shares, sees a compelling outlook for Vera.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics’ Atacicept Positioned for Growth Amid Market Overreaction to Otsuka’s Sibeprenlimab
- Vera Therapeutics selloff Friday overblown, says JPMorgan
- 3 Best Stocks to Buy Now, 2/18/2025, According to Top Analysts
- Buy Rating Affirmed for Vera Therapeutics Amid Promising Atacicept Prospects and Market Overreaction Concerns
- Vera reaction to competitor IgAN update ‘overdone,’ says Goldman Sachs